BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/26/2018 2:31:05 AM | Browse: 1085 | Download: 1635
 |
Received |
|
2017-10-29 03:44 |
|
Peer-Review Started |
|
2017-10-29 05:08 |
|
To Make the First Decision |
|
2017-11-30 06:09 |
|
Return for Revision |
|
2017-12-01 03:55 |
|
Revised |
|
2017-12-10 11:58 |
|
Second Decision |
|
2017-12-19 11:24 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2017-12-20 02:21 |
|
Articles in Press |
|
2017-12-20 02:21 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2017-12-25 08:21 |
|
Typeset the Manuscript |
|
2018-01-22 08:50 |
|
Publish the Manuscript Online |
|
2018-01-26 02:31 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Early prediction of survival in hepatocellular carcinoma with transarterial chemoembolization plus sorafenib
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xiao-Chun Meng, Bing-Hui Chen, Jing-Jun Huang, Wen-Sou Huang, Ming-Yue Cai, Jing-Wen Zhou, Yong-Jian Guo and Kang-Shun Zhu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81371655 |
| National Natural Science Foundation of China |
81571774 |
| Guangdong Natural Science Foundation |
2014A030313171 |
|
| Corresponding Author |
Kang-Shun Zhu, MD, Doctor, Doctor, Department of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital of Guangzhou Medical University, 250 East Changgang Road, Guangzhou 510260, Guangdong Province, China. zhukangshun@gzhmu.edu.cn |
| Key Words |
Hepatocellular carcinoma; Transarterial chemoembolization; Sorafenib; Survival; Prognosis |
| Core Tip |
There are no clinical data/markers to early predict improved survival in patients with advanced-stage hepatocellular carcinoma treated with transarterial chemoembolization combined with sorafenib (TACE-S). In this study, we found that mRECIST-evaluated disease control (complete response, partial response and stable disease) at the first follow-up 4-6 wk after TACE-S can be used as an early indicator of better survival from TACE-S. We also found that patients with previous TACE and portal vein tumor thrombus had a poor survival. |
| Publish Date |
2018-01-26 02:31 |
| Citation |
Meng XC, Chen BH, Huang JJ, Huang WS, Cai MY, Zhou JW, Guo YJ, Zhu KS. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib. World J Gastroenterol 2018; 24(4): 484-493 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i4/484.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i4.484 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
